Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients

PURPOSE: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GISTs). Imatinib, sunitinib and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Garner, Andrew P., Gozgit, Joseph M., Anjum, Rana, Vodala, Sadanand, Schrock, Alexa, Zhou, Tianjun, Serrano, Cesar, Eilers, Grant, Zhu, Meijun, Ketzer, Julia, Wardwell, Scott, Ning, Yaoyu, Song, Youngchul, Kohlmann, Anna, Wang, Frank, Clackson, Tim, Heinrich, Michael C., Fletcher, Jonathan A., Bauer, Sebastian, Rivera, Victor M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4233175/
https://ncbi.nlm.nih.gov/pubmed/25239608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1397
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados